WCLC 2025 - Posters & ePosters-P3.12.23 Tepotinib Efficacy in Poor Performance Status and Elderly Patients With MET Exon 14 Skipping NSCLC: A RELA-MET Subanalysis

P3.12.23 Tepotinib Efficacy in Poor Performance Status and Elderly Patients With MET Exon 14 Skipping NSCLC: A RELA-MET Subanalysis

Back to course

Pdf Summary

This REAL-MET subanalysis evaluated the efficacy of tepotinib in treating MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) patients, focusing particularly on underrepresented subgroups with poor performance status (PS) and the elderly. Conducted across six Japanese hospitals, this multicenter retrospective real-world study included 79 patients treated with tepotinib between August 2020 and December 2024.<br /><br />While prior clinical trials, such as the VISION study, established tepotinib's efficacy, real-world data in populations with poor PS (especially PS 2) and elderly patients (age ≥75) have been limited. This study aimed to bridge that gap by analyzing progression-free survival (PFS) and overall survival (OS) outcomes across different PS and age subgroups.<br /><br />Key findings showed that patients with PS 2 exhibited significantly improved PFS compared to those with poor PS of 3–4 (hazard ratio [HR] 7.47, p=0.008) and a trend toward better OS (HR 3.81, p=0.098), supporting treatment use even in PS 2 patients. Elderly patients (≥75 years) demonstrated similar baseline characteristics and clinical outcomes to younger patients (<75 years), with no statistically significant difference in PFS (HR 1.85, p=0.21) or OS (HR 2.05, p=0.09). Notably, OS data remained immature, especially among younger patients whose median OS was not reached at analysis.<br /><br />Subgroup analyses also highlighted that PS 2 patients had fewer elderly individuals and lower PD-L1 expression compared to patients with better PS (0–1). Overall, these results reinforce tepotinib's clinical utility across diverse real-world patient populations, including those traditionally less represented in trials, such as elderly patients and those with moderate functional impairment. The data endorse tepotinib as an effective treatment option regardless of age or moderate poor performance status.

Asset Subtitle

Kazuhiro Nishiyama

Meta Tag

Speaker Kazuhiro Nishiyama

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

tepotinib

MET exon 14 skipping

non-small cell lung cancer

poor performance status

elderly patients

progression-free survival

overall survival

real-world study

Japanese multicenter study

PD-L1 expression